IL3RA and leukemia: Given the consistent hematological toxicities observed in a preclinical model of human leukemia treated with CAR T 123, three different strategies for T cell termination have been explored: (i) Short-persisting messenger RNA-modified CD123-redirected CAR T cells (RIVA-CAR T 123); (ii) lentivirally transduced CD123-redirected CAR T cells (CAR T 123), subsequently depleted with the anti-CD52 monoclonal antibody Alenutuzumab and (iii) CAR T 123 co-expressing surface CD20 protein (CAR T 123-CD20), subsequently depleted with the anti-CD20 monoclonal antibody Rituximab [157].